



# A review of the clinical and epidemiological aspects of Guillain-Barré syndrome in patients infected with SARS-CoV-2: An Extended Comprehensive Review

Revisión de los aspectos clínicos y epidemiológicos del Síndrome de Guillain-Barré en pacientes infectados con SARS-CoV-2: Una revisión extensa y comprensiva

Alexander Cordero-Campos<sup>1,a</sup> , José Camones-Huerta<sup>1,2,a</sup> , Leslie Condori-Quispe<sup>1,a</sup> , Susana Guzman-Carrasco<sup>1,a</sup> , Gustavo A. Quispe-Villegas<sup>1,a</sup> , Karina Chin-Wu<sup>1,a</sup> , Kenneth Vargas-Suarez<sup>1,a</sup> , Hugo Umeres-Cáceres<sup>1,3,b</sup> , Martín Tipismana-Barbarán<sup>1,3,b</sup> 

## ABSTRACT

Since 2019, cases of patients with COVID-19 who developed Guillain-Barré Syndrome (GBS) have been reported. This review explores mechanisms that explain pathophysiology, clinical features, laboratory findings, and imaging characteristics in these patients. **Methodology:** A bibliographic search was made of studies on the topic published in NCBI and Scielo, between December 2019 and April 2022. **Results:** Ninety articles were found, 53 of which were included in this article. No studies were found that explain an association between GBS and COVID19. Specific clinical manifestations found were areflexia (56.95%), hyporeflexia (19.44%), muscle weakness (65.28%), gait disturbance (12.5%), hypoesthesia (26.39%), paresthesia (30.55%), and micturition disturbance (6.94%). The CSF findings included albumin-cytological dissociation (66.67%), and an average protein level of 140.23 mg/dL (SD: 106.71). Some cases reported enhancement of the cervical leptomeningeal, brainstem and cranial nerves on magnetic resonance imaging tests. The predominant variant of GBS was acute inflammatory demyelinating polyneuropathy (56.94%). The findings in the nerve conduction studies were the absence of F waves (61.54%), increased distal motor latency (80%), decreased motor amplitude (93.1%), and decreased motor conduction velocity (75%). In addition, the nerves mainly involved were the tibial (20.21%), peroneal (24.47%), median (20.21%), and ulnar (18.09%). The most frequent alteration of cranial nerves was bilateral (25%) and unilateral (13.89%) facial palsy. **Conclusion:** The most common GBS variant was Acute Inflammatory Demyelinating Polyneuropathy. Cerebrospinal fluid analysis revealed albumin-cytological dissociation as the most common finding, and MRI tests showed cranial nerves enhancements. An additional differential feature was the lower commitment of the autonomous system.

**Keywords:** Guillain-Barré, SARS-CoV-2, COVID-19

## RESUMEN

Desde 2019, se han venido publicando casos de pacientes con COVID-19 que desarrollaron el Síndrome de Guillain-Barré (GBS). Esta revisión explora mecanismos que expliquen fisiopatología, características clínicas, hallazgos de laboratorio y características imagenológicas en estos pacientes. **Metodología:** Búsqueda bibliográfica de estudios publicados en NCBI y Scielo, entre diciembre de 2019 y abril de 2022. **Resultados:** Se encontraron noventa

<sup>1</sup> School of Medicine, Universidad Peruana Cayetano Heredia, Lima-Perú

<sup>2</sup> Instituto de Medicina Tropical y Enfermedades Infecciosas Alexander Von Humboldt

<sup>3</sup> Neurology department, Hospital Cayetano Heredia, Lima-Perú

<sup>a</sup> Medical student

<sup>b</sup> Neurologist

artículos, 53 de los cuales se incluyen esta síntesis. No se encontraron estudios que expliquen una asociación entre GBS y COVID-19. Clínicamente, se encontró arreflexia (56.95%), hiporreflexia (19.44%), debilidad muscular (65.28%), alteración de la marcha (12.5%), hipoestesia (26.39%), parestesia (30.55%) y alteración de la micción (6.94%). Los hallazgos en el líquido cefalorraquídeo incluyeron disociación albumino-citológica (66.67%) y un nivel promedio de proteínas de 140.23 mg/dL (DE: 106.71). Algunos casos mostraron realce de las leptomeninges cervicales, tronco encefálico y nervios craneales en tests de resonancia magnética. La variante predominante de GBS fue polineuropatía desmielinizante inflamatoria aguda (56.94%). Los hallazgos en los estudios de conducción nerviosa incluyeron ausencia de ondas F (61.54%), aumento de la latencia motora distal (80%), disminución de la amplitud motora (93.1%) y disminución de la velocidad de conducción motora (75%). Los nervios principalmente involucrados fueron el tibial (20.21%), peroneal (24.47%), mediano (20.21%) y cubital (18.09%). La alteración más frecuente de los nervios craneales fue parálisis facial bilateral (25%) y unilateral (13.89%). **Conclusión:** La variante más común del Síndrome de Guillain-Barré (GBS) fue la Polineuropatía Dismielinizante Inflamatoria Aguda. El análisis del líquido cefalorraquídeo reveló una disociación albumino-citológica como el hallazgo más común, y las imágenes en tests de resonancia magnética mostraron incremento de los nervios craneales. Otro hallazgo diferencial fue el menor compromiso del sistema autónomo.

**Palabras clave:** Guillain-Barré, SARS-CoV-2, COVID-19.

## INTRODUCTION

COVID-19 is known to be caused by SARS-CoV-2, an RNA virus with a bilipid membrane containing proteins of crucial relevance for its pathogenesis<sup>1,2</sup>. SARS-CoV-2 is neuroinvasive, neurotropic, and neurovirulent. More than 460,000,000 cases, and around six million deaths due to COVID-19 worldwide<sup>3,4</sup> and more than 3,500,000 cases and approximately 200,000 deaths<sup>3,4</sup> nationally, have been reported. SARS-CoV-2 incubation period is approximately 2 to 7 days, and the infection presents with symptoms such as fever, cough, fatigue, dyspnea, myalgia, and diarrhea<sup>5,6,7</sup>.

Guillain-Barré syndrome (GBS) is an autoimmune disease triggered by bacterial or viral infections<sup>8,9</sup>. It is postulated to be a disorder mediated by an antibody attack on the nerve axolemma, driven by molecular mimicry of microbial surface molecules<sup>10</sup>. Anti-LOS antibodies can bind to the structurally identical glycans present in ganglioside nerves, and anti-ganglioside subclass IgG1 and IgG3 antibodies are complement fixers that bind primarily to gangliosides GM1 and GD1a in acute motor axonal neuropathy<sup>8,10</sup>.

The primary manifestation of GBS is a progressive bilateral weakness that ascends from the lower extremities and can last up to 4 weeks. As well, GBS can involve areflexia, and potential cranial nerve involvement, resulting in symptoms such as numbness, tingling, and weakness, which may progress to paralysis. Other common symptoms are areflexia and cranial nerve involvement. Additionally,

sensory symptoms, ataxia, and autonomic dysfunction can be present<sup>10</sup>.

The most common precipitant of GBS is gastroenteritis caused by *Campylobacter jejuni*: two case-control studies describe up to 26-27% of previous gastroenteritis due to *C. jejuni* compared to controls<sup>11,12</sup>. A report by Hao et al. places influenza A in second place with a 17% incidence. On the other hand, 12.4% of patients with GBS were positive for IgM cytomegalovirus<sup>12</sup>.

Similarly, symptomatic *C. jejuni* infection is associated with up to a 100-fold increased risk of developing GBS during a 2-month follow-up in a Swedish cohort; meanwhile, a case-control study resulted in an odds of up to 60 times in patients with *C. jejuni* enteritis<sup>13,14</sup>. In addition, the background of *C. jejuni* infection is associated with a worse prognosis, defined as a longer time to recover walking without help (90 days vs. 45 days)<sup>11</sup>.

The Zika virus (ZIKV) outbreak has also been associated with GBS. IgM for ZIKV was positive in 93% of cases with GBS<sup>15</sup>. The calculated prevalence for this association was 1.23%<sup>16</sup>.

In Peru, a GBS outbreak occurred in mid-2019; some authors determined that the pure motor subtype (80%) was the most frequent. Most GBS cases were positive for *C. jejuni* IgM as well as for anti-ganglioside antibodies<sup>17</sup>. In a systematic review of case reports in 2020, it was suggested that the onset of GBS took place after the symptoms of COVID-19. In addition, the

variants were associated with bilateral facial palsies, whose mechanism is a post-inflammatory syndrome<sup>18</sup>.

The mechanism behind the association between COVID-19 and GBS is not yet fully understood. However, preliminary studies suggest that the SARS-CoV-2 virus's neuroinvasive and neurotropic properties may play a role in triggering GBS. One theory suggests that SARS-CoV-2 infection can do it through molecular mimicry, where the virus's spike protein (S1) binds to the ACE2 receptor, and S2 fuses the viral membrane with the cell membrane<sup>2</sup>. This interaction may lead to an autoimmune response, causing the body to produce antibodies that can bind to the nerve axolemma and trigger GBS<sup>19,20</sup>.

Despite these findings, the current evidence falls short of establishing a definitive causal relationship between COVID-19 and GBS. The intricate interplay between viral infections and autoimmune responses requires more in-depth exploration. Further research is imperative to unravel the underlying mechanisms and identify specific risk factors contributing to the development of GBS in the context of COVID-19 infections. By elucidating these aspects, we aim to provide a more comprehensive understanding of the relationship between COVID-19 and GBS, contributing valuable insights to the ongoing discourse in the medical community.

## METHODOLOGY

We searched for studies reported from December 2019 to April 2022.

### **Criteria selection:**

*Inclusion criteria:* Observational studies such as case series and case reports, and experimental studies and clinical trials published in Spanish, English and Portuguese. We included the referred studies because at the time of search, these study designs were the most probable to find reliable information regarding SGB presentation in COVID-19 patients.

*Exclusion criteria:* Case-control, and cohort studies, reviews, commentaries, and editorials. Studies written in different languages as referred above. Studies that were no possible to retrieve.

### **Study selection:**

We used the NCBI and Scielo platforms for this automated search, which yielded 257 records. Of

these, we removed 166 considered ineligible studies, i.e., those that not included keywords in titles or abstracts or different topics. We screened 91 articles for full-text consideration. We excluded 38 of them because they were of different types, not considered as inclusion criteria (Appendix 1). In addition, to search for a possible pathophysiological mechanism, the following MESH words were used: ( "Guillain-Barre Syndrome/etiology"[Mesh] OR "Guillain-Barre Syndrome/immunology"[Mesh] OR "Guillain-Barre Syndrome/pathology"[Mesh] OR "Guillain-Barre Syndrome/physiopathology"[Mesh] ) AND ( ("SARS-CoV-2/immunology"[Mesh] OR "SARS-CoV-2/pathogenicity"[Mesh] ) OR (SARS Coronavirus 2 OR Coronavirus 2, SARS OR Coronavirus Disease 2019 Virus OR 2019 Novel Coronavirus OR Coronavirus, 2019 Novel OR Novel Coronavirus, 2019 OR SARS-CoV-2 Virus OR SARS CoV 2 Virus OR SARS-CoV-2 Viruses OR Virus, SARS-CoV-2 OR 2019-nCoV OR COVID-19 Virus OR COVID 19 Virus OR COVID-19 Viruses OR Virus, COVID-19 OR COVID19 Virus OR COVID19 Viruses OR Virus, COVID19 OR Viruses, COVID19 OR Severe Acute Respiratory Syndrome Coronavirus 2)).

For the search of clinical manifestations, laboratory findings, and imaging studies of GBS in patients with SARS-CoV-2, the following keywords were used: (SARS Coronavirus 2 OR Coronavirus 2, SARS OR Coronavirus Disease 2019 Virus OR 2019 Novel Coronavirus OR Coronavirus, 2019 Novel OR Novel Coronavirus, 2019 OR SARS-CoV-2 Virus OR SARS CoV 2 Virus OR SARS-CoV-2 Viruses OR Virus, SARS-CoV-2 OR 2019-nCoV OR COVID-19 Virus OR COVID 19 Virus OR COVID-19 Viruses OR Virus, COVID-19 OR COVID19 Virus OR COVID19 Viruses OR Virus, COVID19 OR Viruses, COVID19 OR Severe Acute Respiratory Syndrome Coronavirus 2) AND ( "Guillain-Barre Syndrome/blood"[Mesh] OR "Guillain-Barre Syndrome/cerebrospinal fluid"[Mesh] OR "Guillain-Barre Syndrome/diagnosis"[Mesh] OR "Guillain-Barre Syndrome/pathology"[Mesh] ). We considered the first word building because it provided more records.

## RESULTS

In our search, 91 studies were identified, 38 of which were excluded because they did not accomplish the review objectives. Finally, we included 53 articles (Appendix 2) representing 72 cases (patients) since some studies reported more than one case.

The cases were classified according to COVID-19 diagnosis methods, symptoms, motor and sensory signs, autonomic alteration, antibodies profile, cerebrospinal fluid findings, imaging studies, types of GBS, and findings in nerve conduction studies.

#### COVID-19 diagnosis

Of the 72 cases, 77.68% (n=56) were diagnosed with SARS-CoV-2 infection through reverse transcriptase-polymerase chain reaction (PCR), and 1.39% (n=1) was diagnosed with rapid IgG antibody test. The diagnosis method was not mentioned in 20.83% (n=15) of the patients. However, these patients had high suspicion of COVID-19 due to respiratory symptoms.

#### COVID-19 symptoms

Of the 72 GBS cases with a history of COVID-19, the following symptoms were obtained: 45.83% (n=33) presented cough, 56.94% (n=41), fever, 22.22% (n=16), dyspnea, 16.67% (n=12), dysgeusia with/without hyposmia, 9.72% (n=7), diarrhea, and 9.72% (n=7), headache.

#### Motor signs

Of the 72 patients, 34.72% (n=25) exhibited muscle weakness, with 27.78% (n=20) specifically experiencing weakness in the lower limbs, and 2.78% (n=2) in the upper limbs. Meanwhile, 34.72% (n=25) did not report global muscle weakness; such was identified in 11.11% (n=8) of the patients, the first neurological symptom being muscle weakness in the lower limbs. However, in the case reports, it is noteworthy that not all cases provide explicit details regarding the initial symptom. Additionally, only 6.94% (n=5) presented generalized hypotonia, and 2.78% (n=2) exhibited hypotonia exclusively in the lower limbs. Among the cases, 87.5% (n=63) reported no gait abnormality. Nevertheless, 6.94% (n=5) of patients displayed abasia, and 5.56% (n=4) presented paraparesis. Hypotonia was not reported in 90.28% (n=65) of the cases.

None of the patients who presented with muscle weakness in the lower or upper limbs have exhibited another neurological symptom at onset; however, 2 out of 3 patients who did not present muscle weakness debuted with hypotonia in the lower limbs, while one developed ataxia and areflexia. On the other hand, 3 patients who presented with generalized muscle weakness developed ascending paralysis at the onset.

In the deep tendon reflexes evaluation, 40.28% (n=29) presented global areflexia; specifically, 15.28% (n=28) presented areflexia in the lower limbs and 1.39% (n=1) in the upper limbs. The 19.44% (n=14) developed hyporeflexia in the lower limbs, upper limbs, and globally in 8.33% (n=6), 4.17% (n=3), and 6.94% (n=5) respectively compared to the 80.56% (n=58) of patients hyporeflexia was not reported. The only case that presented hyperreflexia did so in the upper limbs, representing 1.39% (n=1). Only 2.78% (n=2) of the patients showed bulbar weakness. Another patient presented a Babinski sign, 1.39% (n=1), and 5.56% (n=4) of the cases presented ataxia.

#### Sensory symptoms

16.67% (n=12) of the patients presented hypoesthesia in both lower and upper limbs. While 8.33% (n=6) presented it only in the lower limbs, and 1.39% (n=1) presented it only in the upper limbs. 73.61% (n=53) of the patients did not report this symptom. Only one patient presented hyperesthesia in the back.

Likewise, paresthesia was reported in both upper and lower limbs in 6.94% (n=5) of the patients, 20.83% (n=15) only in the lower limbs, and 2.78% (n=2) only in the upper limbs. The remaining 69.44% (n=50) did not report paresthesia. Back pain was also reported in 16.66% (n=12) of the patients.

#### Cerebrospinal Fluid (CSF) Findings

The mean CSF protein level was 140.23 mg/dL (SD: 106.71; Min: 37; Max: 620 mg/dL). Furthermore, albumin-cytologic dissociation was reported in 66.67% (n=48) of all cases observed. The absence of that dissociation was reported in 12.50% (n=9). However, the analysis for such dissociation was not reported in 20.83% (n=15).

#### Autonomic dysfunction

It was reported that 2.78% (n=2) of the patients presented fecal incontinence, while urination disturbances were reported in 6.94% (n=5) of all patients. Of the 72 cases, 2.78% (n=2) showed altered blood pressure same as 2.78% (n=2) of patients with impaired heart rate. Finally, only 1.39% (n=1) presented diarrhea.

#### Antibodies

Of the 72 reported cases, 31 were tested for antiganglioside antibodies, and 6.45% (n=2) of the

patients had positive antibody titers. One of them had positive anti-GM2 and anti-GD3 IgM, and anti-GT1b IgG, while the other patient had positive anti-Gal-C antibodies.

### Imaging findings

#### *Plain radiography*

Ten cases were reported with abnormal findings on chest X-rays: Infiltrates with alveolar pattern 10% (n=1), interstitial pattern 10% (n=1), alveolar-interstitial 10% (n=1) or unspecified pattern 70% (n=7), characteristically diffuse 20% (n=2), distributed bilaterally 60% (n=6) or unilaterally 20% (n=2). In addition, multilevel degenerative changes were found on a spinal radiograph.

#### *Computed tomography*

Seven cases were reported with abnormal findings on chest CT: Ground-glass opacities with bilateral distribution 57.14% (n=4) and located at basal 28.57% (n=2) or subpleural 14.29%(n=1) areas. On a brain CT, chronic ischemic encephalomalacia was found in the right occipital lobe.

#### *Magnetic resonance imaging*

Eleven cases with abnormal MRI findings were reported. In brain T1-weighted images, there were 9 cases of enhancement of cranial nerves such as optic 22.22% (n=2), oculomotor 22.22% (n=2), trigeminal 11.11% (n=1), trochlear 11.11% (n=1) and vagus 11.11% (n=1) nerves, as well as enhancement of associated structures like the olfactory bulb 11.11%

(n=1) and Tenon's capsule 11.11% (n=1). In brain T2-weighted images, hyperintensity of the left oculomotor nerve 50% (n=1) and inflammation of the right hippocampus 50% (n=1) were found.

Spinal T1-weighted images showed enhancement in five structures: cervical leptomeninges at 28.57% (n=2), brainstem at 28.57% (n=2), C6-C7 nerve roots at 14.29% (n=1) or posterior nerve roots from T11 14.29% (n=1), and cauda equina 14.29% (n=1). In spinal T2-weighted images, alterations were found in 3 structures: hyperintensity of T7-T12 thoracic medulla 25% (n=1), stenosis of cervical 25% (n=1), and lumbar 50% (n=2) canals.

### Types of Guillain-Barré syndrome in the presence of COVID-19

The most frequent type reported was Acute inflammatory demyelinating polyneuropathy (AIDP) presented in 56.94 % (n= 41) of all cases observed (Figure 1). The second most frequent type was Acute motor axonal neuropathy (AMAN), which represented 13.89% (n=11). The third type was Acute motor and sensory axonal neuropathy (AMSAN) in 12.50% (n= 9). Likewise, a Miller Fisher type 1.39% (n=1) and an overlap between AMAN and Miller Fisher 1.39% (n=1) were reported. Finally, 13.89% (n=10) of cases did not specify the type of GBS.


### Findings of nerve conduction study

These findings were subclassified into the presence of F waves, distal latency, motor conduction amplitude and velocity, and nerve involvement (Table 1).

**Table 1.** Characteristics of nerve conduction studies

F waves	n	%
Present (%)	10	38.46
Absent (%)	16	61.54
Distal motor latency		
Increased (%)	24	80
Preserved (%)	6	20
Motor amplitude		
Decreased (%)	27	93.1
Conserved (%)	2	6.9
Motor conduction velocity		
Decreased (%)	18	75
Preserved (%)	6	25

### TYPES OF GUILLAN BARRÉ SYNDROME



**Figure 1.** Frequency of GBS types found in patients infected with COVID-19.

#### *F waves*

Twenty-six analyses of F waves were reported, of which 38.46% (n=10) presented F waves, and 61.54% (n=16) were absent.

#### *Distal motor latency*

Thirty results of distal motor latency were reported, 20% (n=6) maintained it preserved, while the remaining 80% (n=24) presented increased latency.

#### *Motor amplitude*

Twenty-nine analyses of motor amplitude were reported, 93.1% (n=27) of them presenting decreased motor amplitude, while 6.9% (n=2) remained preserved.

#### *Motor conduction velocity*

Twenty-four analyses of motor conduction velocity were reported, 75% (n=18) of them presented decreased velocity, and 25% (n=6) remained within the reference values.

#### *Type of nerve*

Nerve involvement was reported in 38 studies. They were classified into three groups: upper limbs, lower limbs, and cranial nerves (Table 2). In the upper limbs, median (n=19), ulnar (n=17), and radial (n=1) nerves were involved. In the lower limbs, the nerves involved were tibial (n=28), peroneal (n=23), and sural (n=1). The cranial nerves (CP) involved were CP III (n=1), CP VI (n=1), CP VII (n=2), and CP VIII (n=1). It should be noted that more than one type of nerve was involved in the same patient. In 34 studies, no nerve involvement was reported.

Facial palsy was presented by 38.89% (n=28) of the patients, of which 25% (n=18) was bilateral, and 13.89% (n=10) was unilateral (Figure 2).

**Table 2.** Affected nerves according to the characteristics of nerve conduction studies\*

	n	%	%'
Upper limbs			
Median nerve	19	51.35	20.21
Ulnar nerve	17	45.95	18.09
Radial nerve	1	2.70	1.06
Lower limbs			
Tibial nerve	28	53.85	29.79
Peroneal nerve	23	44.23	24.47
Sural nerve	1	1.92	1.06
Cranial nerves			
CN III	1	20	1.06
CN VI	1	20	1.06
CN VII †	2	40	2.13
CN VIII	1	20	1.06


\* There were patients with more than one nerve involved.

† Involvement of CN VII (facial nerve) was found clinically in 28 patients, described in more detail in Figure 2.

% Percentage based on the classification of affected nerves.

%' Percentage based on the involvement of all affected nerves.

#### FACIAL PALSY



**Figure 2.** Frequency of GBS types found in patients infected with COVID-19.

In addition, it was reported that 11.11% (n=8) of the patients presented dysphagia, while the other 88.89% (n=64) did not.

#### GBS treatment

Of the 72 cases, treatment was only reported in 65 patients, of which 92.31% (n=60) received intravenous immunoglobulin, while 4.62% (n=3) and 3.08% (n=2) received plasmapheresis, and intravenous immunoglobulin with plasmapheresis, respectively.

## DISCUSSION

Pathophysiology of GBS associated with COVID-19 and its relationship with the results

Within the hypotheses of coinfection with SARS-CoV-2, autoimmunity is proposed as a mechanism of molecular mimicry, and a parainfectious phenomenon dependent on the cytokine storm caused by the COVID-19 condition.<sup>21,22</sup> The first hypothesis is supported by the development of symptoms between 3 days to 6 weeks after the respiratory infection, cytological albumin dissociation, PCR negativity for SARS-CoV-2 in the CSF, and improvement by treatment with intravenous immunoglobulin.<sup>21,23</sup> On the other hand, the cytokine storm hypothesis maintains that, following the intracellular invasion of SARS-CoV-2, active replication begins, generating new viral copies that induce pyroptosis of the infected cell and the release of Damage-Associated Molecular Patterns (DAMPs). This process triggers the death of lung cells by activating a local immune response, with the sensitization of macrophages and monocytes responding to the release of cytokines, along with the involvement of T and B lymphocytes. In cases where the immune response is inefficient, subsequent pyroptosis allows the recognition of DAMPs, prolonging inflammation and leading to an increased secretion of pro-inflammatory cytokines such as IL-6, IFN $\gamma$ , IP-10, and MCP1. This excess cytokine secretion may trigger a loss of control of the immune system, potentially resulting in a cytokine storm.<sup>24-30</sup>

One significant theory suggests that SARS-CoV-2 infection may initiate GBS through molecular mimicry, a mechanism proposed within the framework of coinfection with SARS-CoV-2. This hypothesis posits that autoimmunity, fueled by molecular mimicry, plays a pivotal role. The virus's spike protein binding to the ACE2 receptor triggers an autoimmune response, leading to the production of antibodies. These antibodies, in turn, target the nerve axolemma, potentially triggering the onset of Guillain-Barré syndrome<sup>19,20</sup>.

In the autoimmunity hypothesis, autoantibodies attack complexes on glycoproteins surfaces since the Spike protein binds to saccharides and gangliosides of peripheral nerves. However, there is little evidence showing this association.<sup>22,31</sup> In addition, anti-ganglioside antibodies (GD1a/GD1b) are usually found affecting the cranial nerves and are associated with the GBS axonal phenotype; however, the predominance

of the demyelinating phenotype and the absence of anti-ganglioside antibodies do not allow us to establish a relationship between the axonal phenotype, COVID-19 and anti-ganglioside antibodies<sup>22,32</sup>.

In a study on mice infected with SARS-CoV in 2007, an increase in cytokines and chemokines was observed in the cerebrospinal fluid, including interleukins (IL-6, -8) and TNF- $\alpha$ , indicating an inflammatory response at the nervous system level.<sup>33</sup>

In the year 2000, a study analyzing five individuals who succumbed to SARS-CoV and five control subjects determined the presence of SARS-CoV RNA and antigen in the brain region. This suggests that the virus directly affects the central nervous system, causing damage to peripheral nerves, thereby indicating a potential mechanism of direct harm.<sup>34</sup>

Predisposing factors have been evidenced, such as intestinal dysbiosis associated with COVID-19, which correlates with an imbalance in the immune system. This is explained by the role of the microbiota in regulating the balance of Th17 cells and regulatory T cells.<sup>35</sup> There is also a similarity in the microbiota of patients infected with SARS-CoV-2 and patients with autoimmune diseases such as Systemic Lupus Erythematosus; both exhibit a loss of microbiota biodiversity, an increase in pathobionts, and a decrease in symbionts associated with anti-inflammatory properties.<sup>36</sup>

Furthermore, it has been observed that certain medications used during the pandemic to treat COVID-19 could be linked to the development of GBS. A 1998 study revealed that the use of immunosuppressive medications could promote the growth of gastrointestinal infections caused by *C. jejuni*, potentially inducing Guillain-Barré Syndrome.<sup>37</sup> It is known that this bacterium exhibits cross-reactivity with viral antigens, which could contribute to the development of the mentioned syndrome.<sup>38</sup>

### Motor symptoms

We found that predominantly 11.11% (n=8) of the patients the first neurological symptom was muscle weakness in the lower limbs compared to what was reported by *Meythaler et al.*, where 60% (n=42) initially presented it in lower limbs and 20% (n=14) in upper limbs.<sup>39</sup> After that study, *Cosi et al.* similarly, 56% reported initial muscle weakness in the lower limbs, 12% in the upper limbs, and up to 32% in a generalized way.<sup>40</sup> However, in our study,



it is noteworthy that only some cases offered specific information about the initial manifestation, such as lower limb weakness, while others provided more general descriptions.

In the same study by *Cosi et al.*, a case of ataxia, and 4.76% of paraparesis<sup>40</sup> were reported. In our review, we found only 5.56% (n=4) of cases that presented ataxia, and 6.94% (n=5) abasia, while 5.56% (n=4) reported paraparesis.

#### Sensory symptoms

Wang et col. reported 32.50% (n=170) with paresthesia, and 30.78% (n=161) with hypoesthesia and numbness.<sup>41</sup> In our review, paresthesia was also described, as being more frequent in lower limbs at 20.83% (n=15), followed by both lower and upper limbs at 6.94% (n=5) and 2.78% (n=2) just in upper limbs. The same authors also reported hypoesthesia, 16.67% (n=12) in both lower and upper limbs, 8.33% (n=6) in lower limbs, and 1.39% (n=1) in upper limbs.<sup>41</sup> However, we reviewed only one patient who presented hyperesthesia in the back, while in the retrospective study, hyperesthesia was not reported.

Back pain was present in 16.66% (n=12) in our review. However, other authors reported that 34.5% (n=87) had back pain, of which 29.9% (n=26) reported lower back pain.<sup>42</sup>

#### Autonomic Dysfunction

In 2020, a study evaluated 118 patients, of which 41.53% (n=49) reported at least one type of autonomic dysfunction.<sup>43</sup> The most common were defecation dysfunction, including constipation (n=26) and diarrhea (n=25), followed by blood pressure abnormalities (n=23).<sup>43</sup> Additionally, urinary retention (n=18) and heart rate abnormalities were found (n=16).<sup>43</sup> In our review, only 13.89% (n=10) found at least one type of autonomic alteration; the most frequent being the alteration of urination followed by fecal incontinence. While blood pressure and heart rate abnormalities were found in two patients. Besides, only one patient presented diarrhea. Therefore, we found autonomic dysfunction was less frequent during the COVID-19 pandemic.

#### Cranial nerves (CN) compromise

In a study conducted in 2014, of 68 patients with GBS, 62.3% (n=38) presented at least one CN compromise, being the most common bulbar paralysis

and dysphagia (n=30), followed by facial paralysis (n=28) where only three had a unilateral compromise.<sup>44</sup> The least common CN compromise were hypoglossal (n=6), ophthalmoplegia (n=4), and vestibulocochlear nerve dysfunction (n=1).<sup>44</sup> In our review, cranial nerve involvement was clinically described in 38.89% (n=28) and reported on electromyography in 6.94% (n=5), much lower than before the COVID-19 pandemic. Regarding CN compromise, the most common was bulbar palsy causing dysphagia; In comparison with the findings of our review, the most frequent finding was facial paralysis reported clinically in 38.89% (n=28) and 2.78% (n=2) by electromyography. <sup>44</sup> It is worth mentioning that, in both cases, bilateral bulbar palsy predominated over unilateral.

#### The Role of cerebrospinal fluid (CSF) analysis

An important laboratory finding of GBS is albuminocytological dissociation, representing the increase of CSF albumin in the absence of hypercellularity.<sup>45</sup> However, around 30-50% of patients do not experience significant CSF protein increase during the first week; and 10-30% during the second.<sup>45</sup> Because of these findings, a normal protein count cannot rule out GBS. However, our findings suggest the consistency of this finding along the SGB cases associated with COVID-19. In addition, one patient was reported positive for SARS-CoV-2 by RT-PCR in CSF, but the rest were negative.

#### Radiological Imaging in the Context of GBS and COVID-19

In the first months of the COVID-19 breakthrough, Wong et al. and Chung et al. reported radiological features associated with COVID-19 pneumonia in X-ray imaging and CT scans. Among the principal findings, ground glass opacity and consolidations are predominantly at the peripheral level, typically involving both lungs.<sup>46,47</sup> Nevertheless, imaging findings between isolated COVID-19 and co-infection with GBS do not differ significantly.

MRI scans have limited diagnostic accuracy for GBS diagnosis but may be useful in atypical presentations. Before 2019, root nerve contrast enhancement was reported as a common MRI finding, especially at the cauda equina and conus medullaris levels in lumbar MRI<sup>48-52</sup>.

This revision highlights the same MRI characteristics for GBS patients with COVID-19 coinfection. In addition, enhancement of the cervical

leptomeningeal level and brainstem were reported (18%), alongside foraminal stenosis (18%).

#### GBS variants and COVID-19 coinfection

The first case series and observational studies describe a symptomatic resemblance between SARS-CoV-2 infection and GBS.<sup>53</sup> During the outbreak, a review reported Acute Inflammatory Demyelinating Polyneuropathy (AIDP) as the principal variant in 26 patients (59.1%)<sup>54</sup>. However, before the pandemic, AIDP frequency peaked at 85-90%, followed by Acute Motor Axonal Neuropathy (AMAN) and Acute Motor-Sensitive Axonal Neuropathy (AMSAN) at 5-10%.<sup>55,56</sup> However, in our review, both AMAN and AMSAN variants were found in 13.89% and 12.5%, respectively. So, it seems that the frequencies may have increased.

Less common variants like Miller-Fisher Syndrome (MF) or Bickerstaff Encephalitis were also reported.<sup>57</sup> Even after the SARS-Cov-2 outbreak, both GBS variants did not experience an increase. Finally, 10 cases were cataloged as non-otherwise specified GBS, probably because of the unavailability of neurophysiological testing.

#### Nerve conduction studies and GBS

In 2021, a retrospective report of 31 clinical cases found 84% of abnormal F waves (prolonged or absent latency), 65% presented a prolonged distal motor latency at least in one nerve, and a decrease of conduction velocity in 52% of patients.<sup>58</sup> Our findings also support the predominance of the absent F wave in most co-infection cases.

In another case-control study published in 2016, it was reported that all evaluated patients presented a prolonged distal motor latency and a reduction in motor amplitude (n=37) in the median, ulnar, and peroneal nerves.<sup>59</sup> Notably, in the first week of illness, motor conduction velocity was decreased in the median and peroneal nerves and preserved in the ulnar nerve.<sup>59</sup> The results found in our review are similar to these findings, as prolonged distal motor latency and decreased motor conduction velocity were the most frequent findings. However, in our findings, ulnar nerve involvement (44.74%) was evident, being the second most frequent after the median nerve (50%).

#### CONCLUSIONS

To our knowledge, this work represents a most complete and comprehensive analysis of COVID-19

and SGB. So here we resume our principal results. The most common type of GBS-COVID-19 association was acute inflammatory demyelinating polyneuropathy (AIDP). This variant was also frequent before the pandemic, indicating no distinct predominance in SARS-CoV-2 infected patients. The clinical findings in our review revealed that paresthesia predominantly in the lower limbs and hypoesthesia in the upper and lower limbs were the most frequent sensory abnormalities, along with back pain. Regarding motor function, global muscle weakness was the most common alteration.

Similarly, nerve conduction findings in patients during the pandemic were comparable to those observed in patients with GBS before the pandemic, with the most common abnormality being the absence of F waves.

Autonomic abnormalities were less prevalent in patients with SGB-COVID-19 association compared to cases reported before the pandemic, with the most frequent autonomic abnormalities in this review were urinary alterations, which were not as frequent in pre-pandemic cases, whereas defecation alterations were more common.

Regarding cranial nerve involvement, facial paralysis was the most common in our review compared to cases before the pandemic, where bulbar paralysis was more frequent. The only similarity was that bilateral facial paralysis predominated over unilateral paralysis. It is important to note that the prevalence in our review was much lower compared to pre-pandemic SGB cases.

The most frequent characteristics found in cerebrospinal fluid (CSF) analysis were elevated protein levels and albumin-cytological dissociation, which did not differ from cases reported before the pandemic.

Based on magnetic resonance imaging (MRI) reports, the most common characteristic was nerve roots and cranial nerve enhancement. However, additional findings included cervical leptomeningeal and brainstem enhancement (18%) and foraminal stenosis (18%) in lumbar MRI scans.

**Author contributions: ACC, JCH, LCQ, SGC, GQV, KCW, KVS:** Conceptualization, methodology, Software, Validation, Formal Analysis, Investigation, Resources, Data curation and Writing-original draft preparation. **JCH, ACC, and HUC:** Writing-

Review & Editing. **HUC, MTB**: Conceptualization, Methodology, Visualization, Supervision, Funding acquisition. **ACC & JCH**: Project administration. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of interest:** The authors declare no conflict of interest.

### Acknowledgements

We appreciate the support received by our advisers Dr. Tipismana and Dr. Umeres.

### Limitations

Some limitations of our study included the heterogeneity in the presentation of patient progressions, in the reviewed cases and the variability in the severity of their symptoms.

### \*Correspondence:

Alexander Cordero Campos; alexander.cordero.c@upch.pe (ACC)

**Institution address:** Av. Honorio Delgado 430, SMP, Lima-Perú

### REFERENCES

1. Coronavirus [Internet]. Mhmedical.com. [cited March 20, 2022]. Available in: <https://accessmedicina.mhmedical.com/content.aspx?bookid=1507&sectionid=102896371>
2. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nature Communications*. 2020 Mar 27; 11(1):1620.
3. COVID-19 map [Internet]. Johns Hopkins Coronavirus Resource Center. [cited March 20, 2022]. Available in: <https://coronavirus.jhu.edu/map.html>
4. Peru [Internet]. Johns Hopkins Coronavirus Resource Center. [cited March 20, 2022]. Available in: <https://coronavirus.jhu.edu/region/peru>
5. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*. 2020; 382(18): 1708-1720. doi:10.1056/NEJMoa2002032
6. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. *N Engl J Med*. 2020;382(24):2372-2374. doi:10.1056/NEJMc2010419
7. Escobar G, Matta J, Taype-Huamani W, Ayala R, Amado J. Características clínico-epidemiológicas de pacientes fallecidos por COVID-19 en un hospital nacional de Lima, Perú. *Rev Fac Med Hum*. 2020;20(2):180-185. doi:10.25176/RFMH.v20i2.2940
8. Ebrahim Z, Rahmani F, Rezaei N. Autoimmunity and cytokines in Guillain-Barre syndrome revisited: review of pathomechanisms with an eye on therapeutic options. *Eur Cytokine Netw*. 2019; 30(1):1-14. doi:10.1684/ecn.2019.0424
9. Filosto M, Cotti S, Gazzina S, Foresti C, Frigeni B, Servalli M et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. *J Neurol Neurosurg Psychiatry*. 2021;92(7):751-756. doi:10.1136/jnnp-2020-324837
10. Willison H, Jacobs B, van Doorn P. Guillain-Barré syndrome. *Lancet*. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1
11. Rees JH, Soudain SE, Gregson NA, Hughes RA. *Campylobacter jejuni* infection and Guillain-Barré syndrome. *N Engl J Med*. 1995;333(21):1374-1379. doi:10.1056/NEJM199511233332102
12. Hao Y, Wang W, Jacobs BC, Qiao B, Chen M, Liu D, et al. Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. *Ann Clin Transl Neurol*. 2019 Dec; 6(12):2510-2517. doi:10.1002/acn3.50946.
13. McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with *Campylobacter jejuni*. *Am J Epidemiol*. 2001;153(6):610-614. doi:10.1093/aje/153.6.610
14. Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré syndrome and preceding infection with *campylobacter*, influenza and Epstein-Barr virus in the general practice research database. *PLoS One*. 2007;2(4):e344. Published 2007 Apr 4. doi:10.1371/journal.pone.0000344
15. Cao-Lormeau V-M, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *The Lancet*. 2016; 387(10027):1531-9. doi:10.1016/S0140-6736(16)00562-6
16. Barbi L, Coelho AVC, Alencar LCA de, Crovella S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. *The Brazilian Journal of Infectious Diseases*. *Braz J Infect Dis*. 2018;22(2):137-141. doi:10.1016/j.bjid.2018.02.005.
17. Ramos AP, Leonhard SE, Halstead SK, Cuba MA, Castañeda CC, Dioses JA, et al. Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With *Campylobacter jejuni* Infection. *Neurol Neuroimmunol Neuroinflamm*. 2021;8(2):e952. Published 2021 Feb 5. doi:10.1212/NXI.0000000000000952


18. Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA. COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. *Wellcome Open Res.* 2020;5:107. doi:10.12688/wellcomeopenres.15987.2
19. Khan Z, Ahmad U, Ualiyeva D, Amisshah OB, Khan A, Noor Z, et al. Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination?, *Clinical Immunology Communications.* 2022;2:1-5, https://doi.org/10.1016/j.clicom.2021.12.002.
20. Jumagaliyeva MB, Ayaganov DN, Abdelazim IA, Saparbayev SS, Tuychibaeva NM, Kurmambayev YJ. Relation between Guillain-Barré syndrome and Covid-19: Case-Series. *J Med Life.* 2023;16(9):1433-1435. doi: 10.25122/jml-2023-0275.
21. Aasfara J, Hajjij A, Bensouda H, Ouhabi H, Benariba F. A unique association of bifacial weakness, paresthesia, and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report. *Pan Afr Med J.* 2021; 38:1–5. doi:10.11604/pamj.2021.38.30.27646
22. Chakraborty U, Hati A, Chandra A. Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication. *Diabetes Metab Syndr.* 2021;15(6):102326. doi:10.1016/j.dsx.2021.102326
23. Mohammadi SM, Abdi R, Karimi Z, Mortazavi F. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report. *J Med Case Rep.* 2022;16(1):63. doi:10.1186/s13256-021-03245-y
24. Lahiri D, Ardila A. COVID-19 pandemic: a neurological perspective. *Cureus.* 2020; 12:e7889. doi:10.7759/cureus.7889
25. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun.* 2020;87:18-22. doi:10.1016/j.bbi.2020.03.031
26. Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, Memon GM, et al. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. *Front Neurol.* 2020; 11:518. doi:10.3389/fneur.2020.00518
27. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. *J Clin Neurosci.* 2020; 77:8-12. doi:10.1016/j.jocn.2020.05.017
28. Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. *Am J Emerg Med.* 2020;38(7):1549.e3-1549.e7. doi:10.1016/j.ajem.2020.05.024
29. Tay M, Poh C, Rénia L, MacAry P, Ng L. The trinity of COVID-19: immunity, inflammation, and intervention. *Nat. Rev. Immunol.* 2020;20(6):363–374. doi: 10.1038/s41577-020-0311-8.
30. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
31. Diez-Porrás L, Vergés E, Gil F, Vidal MJ, Massons J, Arboix A. Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review. *Neuromuscul Disord.* 2020;30(10):859-861. doi:10.1016/j.nmd.2020.08.354
32. Wada S, Nagasaki Y, Arimizu Y, Shimo M, Matsukuma Y, Okamoto M, et al. Neurological Disorders Identified during Treatment of a SARS-CoV-2 Infection. *Intern Med.* 2020 Sep 1; 59(17):2187–9. doi:10.2169/internalmedicine.5447-20
33. McCray P, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. *J Virol.* 2007 Jan;81(2):813-21. doi: 10.1128/JVI.02012-06. Epub 2006 Nov 1. PMID: 17079315; PMCID: PMC1797474.
34. Arbour N, Day R, Newcombe J, Talbot P. Neuroinvasion by human respiratory coronaviruses. *J. Virol.* 2000;74(19):8913–8921. doi:10.1128/jvi.74.19.8913-8921.2000
35. Ivanov I, Honda K. Intestinal commensal microbes as immune modulators. *Cell Host Microbe.* 2012;12(4):496-508. doi:10.1016/j.chom.2012.09.009
36. Katz-Agranov N, Zandman-Goddard G. Autoimmunity and COVID-19 - The microbiotal connection. *Autoimmun Rev.* 2021;20(8):102865. doi: 10.1016/j.autrev.2021.102865
37. Maccario M, Tarantino A, Nobile-Orazio E, Ponticelli C. *Campylobacter jejuni* bacteremia and Guillain-Barré syndrome in a renal transplant recipient. *Transpl Int.* 1998;11(6):439-442. doi:10.1007/s001470050171
38. Zhang L, Arrington S, Keung Y. Guillain-Barré syndrome after transplantation. *Leuk Lymphoma.* 2008;49(2):291-297. doi:10.1080/10428190701760003
39. Meythaler JM. Rehabilitation of Guillain-Barré syndrome. *Arch Phys Med Rehabil.* 1997;78(8):872-879. doi:10.1016/s0003-9993(97)90203-3
40. Cosi V, Versino M. Guillain-Barré syndrome. *Neurol Sci.* 2006; 27 (Suppl 1): s47–s51. doi:10.1007/s10072-006-0548-4
41. Wang Y, Shang P, Xin M, Bai J, Zhou C, Zhang HL. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study. *BMC Neurol.* 2017; 17: 200. doi:10.1186/s12883-017-0982-3
42. Yao S, Chen H, Zhang Q, Shi Z, Liu J, et al. Pain during the acute phase of Guillain-Barré syndrome. *Medicine (Baltimore).* 2018; 97(34):e11595. doi: doi:10.1097/MD.00000000000011595

43. Singh J, Raja V Sr, Irfan M, Hashmat O, Syed M, Shahbaz NN. Frequency of Autonomic Dysfunction in Patients of Guillain Barre Syndrome in a Tertiary Care Hospital. *Cureus*. 2020;12(12):e12101. doi: 10.7759/cureus.12101
44. Bhargava A, Banakar BF, Pujar GS, Khichar S. A study of Guillain-Barré syndrome with reference to cranial neuropathy and its prognostic implication. *J Neurosci Rural Pract*. 2014;5(Suppl 1):S43-S47. doi:10.4103/0976-3147.145200.
45. Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira M, Cornblath D, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. *Nat Rev Neurol*. 2019; 15: 671-683. <https://doi.org/10.1038/s41582-019-0250-9>.
46. Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. *Radiology*. 2020; 296(2):E72-E78. doi:10.1148/radiol.2020201160
47. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology*. 2020; 295(1):202-207. doi: 10.1148/radiol.2020200230
48. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. *Neurology*. 1996;47(3):813-817. doi:10.1212/wnl.47.3.813
49. Byun WM, Park WK, Park BH, Ahn SH, Hwang MS, Chang JC. Guillain-Barré syndrome: MR imaging findings of the spine in eight patients. *Radiology*. 1998; 208(1):137-141. doi 10.1148/radiology.208.1.9646804
50. Alkan O, Yildirim T, Tokmak N, Tan M. Spinal MRI findings of Guillain-Barré syndrome. *J Radiol Case Rep*. 2009; 3(3):25-28. doi:10.3941/jrcr.v3i3.153
51. Fulbright RK, Erdum E, Sze G, Byrne T al. Cranial nerve enhancement in the Guillain-Barré syndrome. *AJNR Am J Neuroradiol*. 1995; 16(4 Suppl):923-925.
52. Sharma K, Tengsupakul S, Sanchez O, Phaltas R, Maertens P. Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report. *SAGE Open Med Case Rep*. 2019; 7:2050313X19838750. doi:10.1177/2050313X19838750
53. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med*. 2020; 382(26):2574-2576. doi:10.1056/NEJMc2009191
54. Li X, Wang Y, Wang H, Wang Y. SARS-CoV-2-associated Guillain-Barré syndrome is a para-infectious disease. *QJM*. 2021;114(9):625-635. doi:10.1093/qjmed/hcab157
55. Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. *Brain*. 2018; 141(10):2866-2877. doi:10.1093/brain/awy232
56. Ye Y, Wang K, Deng F, Xing Y. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in northeastern China. *Muscle Nerve*. 2013; 47(1):68-71. doi:10.1002/mus.23477
57. Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. *Brain*. 2003;126(Pt 10):2279-2290. doi:10.1093/brain/awg233
58. Gordon PH, Willbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. *Arch Neurol*. 2001; 58(6):913-917. doi:10.1001/archneur.58.6.913
59. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *Lancet*. 2016;387(10027):1531-1539. doi:10.1016/S0140-6736(16)00562-6

Recibido: 09/08/23

Aceptado: 22/12/23

Appendix 1



## Appendix 2

### List of studies included (53)

1. Guillain-Barré syndrome associated with COVID-19 disease (2020)
2. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication (2020)
3. Guillain-Barré Syndrome in a Child With COVID-19 Infection (2020)
4. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of 'long COVID-19 syndrome'? (2020)
5. Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection in a Pediatric Patient (2020)
6. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy (2020)
7. A Case of Guillain-Barré Syndrome Associated With COVID-19 (2020)
8. Guillain-Barré syndrome as only manifestation of COVID-19 infection (2021)
9. COVID-19-associated Guillain-Barre syndrome: Postinfectious alone or neuroinvasive too? (2021)
10. Guillain-Barré syndrome associated with COVID-19 infection: a case from the UK (2020)
11. Miller Fisher syndrome and COVID-19: is there a link? (2020)
12. Guillain-Barré Syndrome Associated with SARS CoV-2 Infection: Case Report (2021)
13. Covid-19 associated Guillain-Barre Syndrome: Contrasting tale of four patients from a tertiary care center in India (2020)
14. Guillain-Barré syndrome associated with COVID-19 infection (2020)
15. Concomitant Guillain-Barre syndrome with COVID-19: a case report (2021)
16. Guillain-Barré syndrome after COVID-19 in Japan (2020)
17. Guillain-Barré syndrome after Covid-19 infection (2020)
18. Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection (2020)
19. Guillain-Barré syndrome related to SARS-CoV-2 infection (2020)
20. The importance of thinking about Guillain-Barré syndrome during the COVID-19 pandemic: a case with pure dysautonomic presentation (2021)
21. Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease (2020)
22. Guillain Barré Syndrome associated with SARS-CoV-2 infection in a patient with a differential diagnosis of dengue (2021)
23. Stridor Due to Cranial Nerve X Palsy Progressing to Polyneuropathy in a Teenager With COVID-19 (2021)
24. Post-COVID-19 bifacial weakness and paresthesia: a case report (2021)
25. Neurological Disorders Identified during Treatment of a SARS-CoV-2 Infection (2020)
26. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report (2022)
27. Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review (2020)
28. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital (2020)
29. A unique association of bifacial weakness, paresthesia, and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report (2021)
30. A possible Guillain-Barré syndrome/transverse myelitis overlap syndrome after recent COVID-19 (2022)
31. A 50-Year-Old Patient with Guillain-Barré Syndrome after COVID-19: A Case Report (2021)
32. Síndrome de Guillain Barré e infección por SARS-CoV-2: reporte de dos casos en Perú (2021)
33. Manifestaciones neurológicas en pacientes pediátricos con COVID-19: Reporte de casos (2021)
34. Intravenous immunoglobulin in COVID-19 associated Guillain-Barré syndrome in pregnancy (2021)
35. Covid-19 associated Guillain-Barre syndrome: A series of a relatively uncommon neurological complication (2021)
36. Guillain Barre syndrome associated with COVID-19 infection: a case report (2020)
37. Guillain-Barre Syndrome and COVID-19: A case report (2020)
38. Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature (2020)

39. Post SARS-CoV-2 Guillain-Barré syndrome (2020)
40. SARS-CoV-2 Associated Guillain-Barre Syndrome with Dysautonomia (2020)
41. Guillain-Barré syndrome and COVID-19: association or coincidence (2020)
42. Otoneurological presentations of COVID-19 (2021)
43. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection (2020)
44. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection (2021)
45. Guillain Barre Syndrome associated with COVID-19 Infection: A Case Report (2021)
46. Guillain-Barré Syndrome after Novel Coronavirus Disease 2019 (2021)
47. Síndrome de Guillain-Barré asociado a infección por SARS-CoV-2 (2020)
48. Síndrome de Guillain-Barré asociado a infección por COVID-19 (2020)
49. A 44-Year-Old Hispanic Man with Loss of Taste and Bilateral Facial Weakness Diagnosed with Guillain-Barré Syndrome and Bell's Palsy Associated with SARS-CoV-2 Infection Treated with Intravenous Immunoglobulin (2020)
50. Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients (2021)
51. Diplejía facial aislada como variante atípica del síndrome de Guillain-Barré tras sospecha de infección por SARS-CoV-2 (2021)
52. Guillain-Barré syndrome with bilateral facial diplegia secondary to severe acute respiratory syndrome coronavirus-2 infection: a case report (2021)
53. An unusual course of SARS-CoV-2 infection: Challenging diagnosis of Guillain-Barré Syndrome (2021)